

CMS Manual System	Department of Health & Human Services (DHHS)
Pub 100-02 Medicare Benefit Policy	Centers for Medicare & Medicaid Services (CMS)
Transmittal 214	Date: December 15, 2015
	Change Request 9367

Transmittal 213, dated November 25, 2015, is being rescinded and replaced by Transmittal 214 since the original transmittal did not include the mean unit cost for Calcitriol 1 mcg/mL oral solution (15ml/bottle) nor the reference to the applicable Healthcare Common Procedure Coding System code for injectable levocarnitine noted in footnote 5 on Attachment B. All other information remains the same.

SUBJECT: Implementation of Changes in the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) for Calendar Year (CY) 2016

I. SUMMARY OF CHANGES: This Change Request implements the CY 2016 rate updates for the ESRD PPS. This recurring update notification applies to Pub. 100-02, Medicare Benefit Policy Manual, chapter 11, section 50.

EFFECTIVE DATE: January 1, 2016

**Unless otherwise specified, the effective date is the date of service.*

IMPLEMENTATION DATE: January 4, 2016

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated)

R=REVISED, N=NEW, D=DELETED-Only One Per Row.

R/N/D	CHAPTER / SECTION / SUBSECTION / TITLE
N/A	

III. FUNDING:

For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding

continued performance requirements.

IV. ATTACHMENTS:

Recurring Update Notification

Attachment - Recurring Update Notification

Pub. 100-02	Transmittal: 214	Date: December 15, 2015	Change Request: 9367
-------------	------------------	-------------------------	----------------------

Transmittal 213, dated November 25, 2015, is being rescinded and replaced by Transmittal 214 since the original transmittal did not include the mean unit cost for Calcitriol 1 mcg/mL oral solution (15ml/bottle) nor the reference to the applicable Healthcare Common Procedure Coding System code for injectable levocarnitine noted in footnote 5 on Attachment B. All other information remains the same.

SUBJECT: Implementation of Changes in the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) for Calendar Year (CY) 2016

EFFECTIVE DATE: January 1, 2016

**Unless otherwise specified, the effective date is the date of service.*

IMPLEMENTATION DATE: January 4, 2016

I. GENERAL INFORMATION

A. Background: Effective January 1, 2011, The Centers for Medicare & Medicaid Services (CMS) implemented the ESRD PPS based on the requirements of section 1881(b)(14) of the Social Security Act (the Act) as added by section 153(b) of the Medicare Improvements for Patients and Providers Act (MIPPA). Section 1881(b)(14)(F) of the Act, as added by section 153(b) of MIPPA and amended by section 3401(h) of the Patient Protection and Affordable Care Act (ACA) established that beginning CY 2012, and each subsequent year, the Secretary shall annually increase payment amounts by an ESRD market basket increase factor, reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act. The ESRD bundled (ESRDB) market basket increase factor minus the productivity adjustment will update the ESRD PPS base rate. Section 217(b)(2) of the Protecting Access to Medicare Act of 2014 (PAMA) included a provision that dictated how the market basket should be reduced for CY 2016.

For CY 2016, in accordance with section 632(c) of the American Taxpayer Relief Act of 2012 (ATRA), CMS conducted an analysis of the case-mix adjustments being used under the ESRD PPS and finalized revisions. Specifically, CMS updated the two-equation regression analysis used to develop the payment adjustments for the CY 2011 ESRD PPS final rule using CY 2012 and 2013 Medicare cost report and claims data. In addition to the case-mix adjustments, CMS also updated the low-volume eligibility criteria and payment adjustment and is implementing a rural payment adjustment. ESRD facilities that submit an attestation to their respective Medicare Administrative Contractors no later than November 1st and meet the criteria at 42 CFR 413.232(b) are eligible to receive the low-volume payment adjustment.

In accordance with section 217(c) of PAMA, CMS implemented a drug designation process for; (1) determining when a product is no longer an oral-only drug; and (2) including new injectable and intravenous products into the ESRD PPS. In addition, CMS is completing a 2-year transition to the updated labor-related share and the most recent core-based statistical area (CBSA) delineations as described in the February 28, 2013 Office of Management and Budget (OMB) Bulletin No. 13-01.

In addition, section 204 of the Achieving a Better Life Experience Act of 2014, provided that payment for oral-only renal dialysis services cannot be made under the ESRD PPS bundled payment prior to January 1, 2025.

The ESRD PPS includes consolidated billing (CB) requirements for limited Part B services included in the ESRD facility's bundled payment. CMS periodically updates the lists of items and services that are subject to Part B consolidated billing and are therefore no longer separately payable when provided to ESRD beneficiaries by providers other than ESRD facilities.

Effective January 1, 2016, Health Care Procedure Coding System (HCPCS) J0886 Injection, epoetin alfa, 1000 units (for esrd on dialysis) will be terminated. All drugs and biologicals used for the treatment of ESRD are the responsibility of the ESRD facility. Practitioner's treating Medicare ESRD beneficiaries with erythropoiesis stimulating agents (ESAs) for reasons other than the beneficiary's ESRD must use the appropriate HCPCS code. Specifically, practitioners should use HCPCS J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units.

B. Policy: Calendar year (CY) 2016 ESRD PPS Updates:

ESRD PPS base rate:

1. A 0.15 percent update to the CY 2015 payment rate. ($\$239.43 \times 1.0015 = \239.79).
2. A wage index budget-neutrality adjustment factor of 1.000495.
3. A refinement budget-neutrality adjustment factor of 0.960319. Therefore, the CY 2016 ESRD PPS base rate is $\$230.39$ ($\$239.43 \times 1.0015 \times 0.960319 = \230.39).

Wage index:

1. The wage index adjustment will be updated to reflect the latest available wage data.
2. The most recent OMB CBSA delineations is fully implemented; therefore, CMS is no longer transitioning the wage index and use of the special wage indicator is no longer necessary for those ESRD facilities that experienced a change in CBSA.
3. The wage index floor will remain at 0.4000.

Labor-related share:

1. The revised labor-related share of 50.673 is fully implemented.

Update to the Patient-Level and Facility-Level Payment Adjustments:

1. For the CY 2016 ESRD PPS refinement CMS is changing the adjustment payment amounts to reflect the updated regression analysis that was completed using CY 2012 and 2013 ESRD claims and cost report data for adult and pediatric patients. These values are available in Tables 1 and 2 respectively of Attachment A in the expanded bundle multipliers column.
2. CMS is implementing a rural payment adjustment for adult ESRD beneficiaries utilizing those ESRD facilities that are located in a rural CBSA (that is, a non-urban CBSA). This value

is available in Table 1 of Attachment A.

Outlier Policy:

As a result of the CY 2016 ESRD PPS refinement, CMS is also changing the adjusters used for determining the Medicare Allowable Payment (MAP) amount in the outlier calculation. These values are available in Tables 1 and 2 of Attachment A in the separately billable multipliers column.

CMS made the following updates to the adjusted average outlier service MAP amount per treatment:

1. For adult patients, the adjusted average outlier service MAP amount per treatment is \$50.81.
2. For pediatric patients, the adjusted average outlier service MAP amount per treatment is \$39.20.

CMS made the following updates to the fixed dollar loss amount that is added to the predicted MAP to determine the outlier threshold:

1. The fixed dollar loss amount is \$86.97 for adult patients.
2. The fixed dollar loss amount is \$62.19 for pediatric patients.

CMS made the following changes to the list of outlier services:

1. Renal dialysis drugs that are oral equivalents to injectable drugs are based on the most recent prices retrieved from the Medicare Prescription Drug Plan Finder, are updated to reflect the most recent mean unit cost. In addition, CMS will add or remove any renal dialysis items and services that are eligible for outlier payment. See Attachment B.
2. The mean dispensing fee of the National Drug Codes (NDC) qualifying for outlier consideration is revised to \$0.97 per NDC per month for claims with dates of service on or after January 1, 2016. See Attachment B.

Consolidated Billing Requirements

The consolidated billing requirements for drugs and biologicals included in the ESRD PPS is updated by:

1. Removing Current Procedural Terminology code 80061 Lipid Panel as it has been determined that this laboratory test is routinely furnished for reasons other than for the treatment of ESRD. Therefore, for dates of service on or after January 1, 2016, the Lipid Panel is no longer subject to the ESRD PPS consolidated billing requirements.
2. Removing HCPCS J0886 injection, epoetin alfa, 1000 units (for esrd on dialysis) since the code will be terminated effective December 31, 2015.
3. Removing HCPCS Q9976 – Injection, Ferric Pyrophosphate Citrate Solution; 0.1 mg of iron since this code will be terminated effective December 31, 2015.

4. Adding HCPCS J1443 - Injection, Ferric Pyrophosphate Citrate Solution; 0.1 mg of iron since this code will be replacing Q9976 and is effective January 1, 2016.

a. J1443 is a drug that is used for anemia management. Anemia management is an ESRD PPS functional category where drugs and biologicals that fall in this category are always considered to be used for the treatment of ESRD. ESRD facilities will not receive separate payment for J1443 with or without the AY modifier and the claims shall process the line item as covered with no separate payment under the ESRD PPS.

b. J1443 is administered via dialysate. Therefore, when billing for J1443, it should be accompanied by the JE modifier as discussed in CR 8256 issued April 26, 2013.

c. In accordance with 42 CFR 413.237(a)(1), HCPCS J1443 is considered to be eligible outlier services and will be included in the outlier calculation when CMS provides a fee amount on the Average Sales Price fee schedule.

Attachment C reflects the items and services that are subject to the ESRD PPS consolidated billing requirements.

II. BUSINESS REQUIREMENTS TABLE

"Shall" denotes a mandatory requirement, and "should" denotes an optional requirement.

Number	Requirement	Responsibility										Other
		A/B MAC			D M E	Shared- System Maintainers				C W F		
		A	B	H H H		F I S S	M C S	V M S				
9367.1	The ESRD PPS Pricer shall include all CY 2016 ESRD PPS updates.											ESRD Pricer
9367.2	FISS shall install and pay claims with the CY 2016 ESRD PPS Pricer for renal dialysis services furnished on or after January 1, 2016.					X						
9367.3	Medicare contractors shall update the provider file for ESRD facilities as necessary to reflect: 1. Attested low volume facilities if applicable; 2. Revised CBSA codes if applicable and where necessary discontinue the special wage indicator; 3. Quality indicator for any applicable QIP adjustments.	X										
9367.4	Medicare contractors shall update the NDC dispensing					X						

Number	Requirement	Responsibility								
		A/B MAC			D M E M A C	Shared- System Maintainers				Other
		A	B	H H H		F I S S	M C S	V M S	C W F	
	fee for ESRD outlier services to \$0.97 for claims with dates of service on or after January 1, 2016.									
9367.5	Medicare contractors shall update the list of items and services that qualify as outlier services according to the updated list in Attachment B, effective January 1, 2016.					X				
9367.6	Medicare contractors shall update the consolidated drug list to: - Remove HCPCS codes 80061, J0886, and Q9976, effective January 1, 2016. Note: New CB List provided as Attachment C.					X			X	
9367.7	Medicare contractors shall update the ESRD consolidated billing edit code list for drugs always considered ESRD with the following new code: J1443 - injection ferric pyrophosphate citrate solution; 0.1 mg of iron, effective January 1, 2016. Note: New CB List provided as Attachment C.					X			X	
9367.8	Medicare contractors shall recognize on the 072x ESRD Type of Bill the new HCPCS: J1443- injection ferric pyrophosphate citrate solution; 0.1 mg of iron	X				X				IOCE
9367.9	Medicare contractors shall not allow a bypass of the consolidated billing edit when the AY modifier is present on 72x types of bill (ESRD) with the following new code: J1443- injection ferric pyrophosphate citrate solution; 0.1 mg of iron	X				X			X	
9367.10	Medicare contractors shall add the rate on the ASP file when it becomes available for the following HCPCS to the computation of the Medicare Allowed Payment					X				

Number	Requirement	Responsibility								
		A/B MAC			D M E	Shared-System Maintainers				Other
		A	B	H H H		F I S S	M C S	V M S	C W F	
	(MAP) amounts (value code 79) used to calculate outlier payments on type of bill 072x: J1443- injection ferric pyrophosphate citrate solution; 0.1 mg of iron									
9367.11	Medicare contractors shall ensure J1443 (injection ferric pyrophosphate citrate solution; 0.1 mg of iron) is reported with the JE modifier on all 072x types of bills (ESRD).					X				

III. PROVIDER EDUCATION TABLE

Number	Requirement	Responsibility				
		A/B MAC			D M E	Other
		A	B	H H H		
9367.12	MLN Article: A provider education article related to this instruction will be available at http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/ shortly after the CR is released. You will receive notification of the article release via the established "MLN Matters" listserv. Contractors shall post this article, or a direct link to this article, on their Web sites and include information about it in a listserv message within 5 business days after receipt of the notification from CMS announcing the availability of the article. In addition, the provider education article shall be included in the contractor's next regularly scheduled bulletin. Contractors are free to supplement MLN Matters articles with localized information that would benefit their provider community in billing and administering the Medicare program correctly.	X				

IV. SUPPORTING INFORMATION

Section A: Recommendations and supporting information associated with listed requirements: N/A

"Should" denotes a recommendation.

X-Ref Requirement Number	Recommendations or other supporting information:
---------------------------------	---

Section B: All other recommendations and supporting information: N/A

V. CONTACTS

Pre-Implementation Contact(s): Shauntari Cheely, shauntari.cheely@cms.hhs.gov ((Claims Processing)) , Michelle Cruse, michelle.cruse@cms.hhs.gov ((ESRD PPS Payment Policy))

Post-Implementation Contact(s): Contact your Contracting Officer's Representative (COR).

VI. FUNDING

Section A: For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

ATTACHMENTS: 3

Attachment A

Table 1: Adult ESRD Beneficiaries

Variable	Separately Billable Multipliers for PY2016	Expanded Bundle Multipliers for PY2016
Age		
18-44	1.044	1.257
45-59	1.000	1.068
60-69	1.005	1.070
70-79	1.000	1.000
80+	0.961	1.109
Body surface area (per 0.1 m ²)	1.000	1.032
Underweight (BMI < 18.5)	1.090	1.017
Time since onset of renal dialysis < 4 months	1.409	1.327
Facility low volume status	0.955	1.239
Comorbidities		
Pericarditis (acute)	1.209	1.040
Gastro-intestinal tract bleeding (acute)	1.426	1.082
Hereditary hemolytic or sickle cell anemia (chronic)	1.999	1.192
Myelodysplastic syndrome (chronic)	1.494	1.095
Rural	0.978	1.008

Table 2: Pediatric ESRD Beneficiaries

Cell	Patient Characteristics		PY 2016 Final Rule	
	Age	Modality	Separately Billable Multipliers	Expanded Bundle Multipliers
1	<13	PD	0.410	1.063
2	<13	HD	1.406	1.306
3	13-17	PD	0.569	1.102
4	13-17	HD	1.494	1.327

Attachment B

Oral and Other Equivalent Forms of Injectable Drugs¹

NDC ²	Drug Product	Mean Unit Cost
30698014301 30698014323 <i>54868346100³</i>	Rocaltrol (calcitriol) 0.25 mcg capsules	\$ 0.71
30698014401	Rocaltrol (calcitriol) 0.5 mcg capsules	\$ 2.29
30698091115	Rocaltrol (calcitriol) 1 mcg/mL oral solution (15ml/bottle)	<i>\$ 12.63</i>
00054000725 00054000713 00093065701 43353063381 00440721599 <i>54868458400³</i> 63304023901 63304023930 <i>67544103581³</i> 23155011801 23155011803 43353003481 43353003409 43353063309 <i>68084047501³</i> <i>68084047511³</i> <i>43353099809⁴</i> <i>60429013301⁴</i> <i>60429013330⁴</i> <i>64380072304⁴</i> <i>64380072306⁴</i>	Calcitriol 0.25 mcg capsules	\$ 0.53
00093065801 <i>54868458200³</i> 63304024001 23155011901 <i>60429013401⁴</i> <i>64380072406⁴</i>	Calcitriol 0.5 mcg capsules	\$ 0.90
00054312041 63304024159	Calcitriol 1 mcg/mL oral solution (15ml/bottle)	<i>\$ 7.20</i>
00074431730	Zemplar (paricalcitol) 1 mcg capsule	<i>\$ 13.26</i>
00074431430	Zemplar (paricalcitol) 2 mcg capsule	<i>\$ 26.55</i>
<i>00074431530³</i>	<i>Zemplar (paricalcitol) 4 mcg capsule</i>	<i>\$ 48.57</i>
00093765656 10888500102 55111066330 60429007830 68382026606	Paricalcitol 1 mcg capsule	\$ 6.48

00093765756 10888500202 55111066430 60429007930 68382026706	Paricalcitol 2 mcg capsule	\$ 12.37
00093765856 10888500302 55111066530 60429008030	Paricalcitol 4 mcg capsule	\$ 24.50
58468012001	Hectorol (doxercalciferol) 0.5 mcg capsule	\$ 14.88
58468012401	Hectorol (doxercalciferol) 1 mcg capsule	\$ 29.75
58468012101	Hectorol (doxercalciferol) 2.5 mcg capsule	\$ 34.53
00054033819 66993018550	Doxercalciferol 0.5 mcg capsule	\$ 11.12
00054038819 66993018650	Doxercalciferol 1 mcg capsule	\$ 21.61
00054033919 66993018750	Doxercalciferol 2.5 mcg capsule	\$ 24.86
54482014407	Carnitor (levocarnitine) 330 mg tablet	\$ 0.87
54482014508	Carnitor (levocarnitine) 1GM/10ML oral solution (118mL/bottle)	\$ 0.27
<i>54482014701⁵</i>	<i>Carnitor (levocarnitine) 1 g/5 mL injection</i>	<i>\$ 6.91</i>
64980050312 50383017104	Levocarnitine 1GM/10ML oral solution (118mL/bottle)	\$ 0.19
64980013009 50383017290	Levocarnitine 330 mg tablet	\$ 0.57

¹ Outlier services imputed payment amounts. Oral or other equivalent forms of Part B injectable drugs included in the ESRD PPS bundle (notwithstanding the delayed implementation of ESRD-related oral-only drugs effective 1/1/2025).

² The mean dispensing fee of the NDCs listed above is **\$0.97**. This amount will be applied to each NDC included fee on the monthly claim. We will limit 1 dispensing per NDC per month. Providers should report the quantity in the smallest available unit. This is necessary because Medicare is using the mean per unit cost in calculating the outlier. For example, if the provider reports NDC 00054312041 Calcitriol 1 mcg/ml oral solution (15/ml/bottle) reported and uses the full 15 ml bottle, the quantity is as 15, not 1. This allows for the most accurate calculation for the outlier.

³ *Effective January 1, 2016, the renal dialysis item and services is no longer an active NDC and therefore does not qualify as an outlier service.*

⁴ *Effective January 1, 2016, the renal dialysis item and service qualifies as an outlier service.*

⁵ *The renal dialysis item or service is an injectable drug and therefore should be reported using the appropriate HCPCS to be eligible for an outlier service. The appropriate HCPCS code is J1955 – Injection, levocarnitine per 1 gm.*

Laboratory Tests

CPT/HCPCS	Short Description
82108	Assay of aluminum

82306	Vitamin d, 25 hydroxy
82379	Assay of carnitine
82570	Assay of urine creatinine
82575	Creatinine clearance test
82607	Vitamin B-12
82652	Vit d 1, 25-dihydroxy
82668	Assay of erythropoietin
82728	Assay of ferritin
82746	Blood folic acid serum
83540	Assay of iron
83550	Iron binding test
83970	Assay of parathormone
84134	Assay of prealbumin
84466	Assay of transferrin
84540	Assay of urine/urea-n
84545	Urea-N clearance test
85041	Automated rbc count
85044	Manual reticulocyte count
85045	Automated reticulocyte count
85046	Reticyte/hgb concentrate
85048	Automated leukocyte count
86704	Hep b core antibody, total
86705	Hep b core antibody, igm
86706	Hep b surface antibody
87040	Blood culture for bacteria
87070	Culture, bacteria, other
87071	Culture bacteri aerobic othr
87073	Culture bacteria anaerobic
87075	Cultr bacteria, except blood
87076	Culture anaerobe ident, each
87077	Culture aerobic identify
87081	Culture screen only
87340	Hepatitis b surface ag, eia

Equipment and Supplies

HPCPS	Short Description
A4657	Syringes with or with needle, each
A4913	Miscellaneous dialysis supplies, not otherwise specified

Attachment C

CY 2016 ESRD PPS CONSOLIDATED BILLING LIST

Note: This is not an all-inclusive list. All injectable drugs and biologicals and their oral or other form of administration, laboratory tests, supplies, and services provided for the treatment of ESRD are included in the ESRD PPS.

DME ESRD SUPPLY HCPCS FOR ESRD PPS CONSOLIDATED BILLING EDITS

HCPC	Long Description
A4216	STERILE WATER, SALINE AND/OR DEXTROSE, DILUENT/FLUSH, 10 ML
A4217	STERILE WATER/SALINE, 500 ML
A4218	STERILE SALINE OR WATER, METERED DOSE DISPENSER, 10 ML
A4450	TAPE, NON-WATERPROOF, PER 18 SQUARE INCHES
A4452	TAPE, WATERPROOF, PER 18 SQUARE INCHES
A6215	FOAM DRESSING, WOUND FILLER, STERILE, PER GRAM
A6216	GAUZE, NON-IMPREGNATED, NON-STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITHOUT ADHESIVE BORDER, EACH DRESSING
A6402	GAUZE, NON-IMPREGNATED, STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITHOUT ADHESIVE BORDER, EACH DRESSING
E0210	ELECTRIC HEAT PAD, STANDARD

DME ESRD SUPPLY HCPCS NOT PAYABLE TO DME SUPPLIERS

HCPC	Long Description
A4215	NEEDLE, STERILE, ANY SIZE, EACH
A4244	ALCOHOL OR PEROXIDE, PER PINT
A4245	ALCOHOL WIPES, PER BOX
A4246	BETADINE OR PHISOHEX SOLUTION, PER PINT
A4247	BETADINE OR IODINE SWABS/WIPES, PER BOX
A4248	CHLORHEXIDINE CONTAINING ANTISEPTIC, 1 ML
A4651	CALIBRATED MICROCAPILLARY TUBE, EACH
A4652	MICROCAPILLARY TUBE SEALANT
A4653	PERITONEAL DIALYSIS CATHETER ANCHORING DEVICE, BELT, EACH
A4657	SYRINGE, WITH OR WITHOUT NEEDLE, EACH

A4660	SPHYGMOMANOMETER/BLOOD PRESSURE APPARATUS WITH CUFF AND STETHOSCOPE
A4663	BLOOD PRESSURE CUFF ONLY
A4670	AUTOMATIC BLOOD PRESSURE MONITOR
A4671	DISPOSABLE CYCLER SET USED WITH CYCLER DIALYSIS MACHINE, EACH
A4672	DRAINAGE EXTENSION LINE, STERILE, FOR DIALYSIS, EACH
A4673	EXTENSION LINE WITH EASY LOCK CONNECTORS, USED WITH DIALYSIS
A4674	CHEMICALS/ANTISEPTICS SOLUTION USED TO CLEAN/STERILIZE DIALYSIS EQUIPMENT, PER 8 OZ
A4680	ACTIVATED CARBON FILTER FOR HEMODIALYSIS, EACH
A4690	DIALYZER (ARTIFICIAL KIDNEYS), ALL TYPES, ALL SIZES, FOR HEMODIALYSIS, EACH
A4706	BICARBONATE CONCENTRATE, SOLUTION, FOR HEMODIALYSIS, PER GALLON
A4707	BICARBONATE CONCENTRATE, POWDER, FOR HEMODIALYSIS, PER PACKET
A4708	ACETATE CONCENTRATE SOLUTION, FOR HEMODIALYSIS, PER GALLON
A4709	ACID CONCENTRATE, SOLUTION, FOR HEMODIALYSIS, PER GALLON
A4714	TREATED WATER (DEIONIZED, DISTILLED, OR REVERSE OSMOSIS) FOR PERITONEAL DIALYSIS, PER GALLON
A4719	"Y SET" TUBING FOR PERITONEAL DIALYSIS
A4720	DIALYSATE SOLUTION, ANY CONCENTRATION OF DEXTROSE, FLUID VOLUME GREATER THAN 249CC, BUT LESS THAN OR EQUAL TO 999CC, FOR PERITONEAL DIALYSIS
A4721	DIALYSATE SOLUTION, ANY CONCENTRATION OF DEXTROSE, FLUID VOLUME GREATER THAN 999CC BUT LESS THAN OR EQUAL TO 1999CC, FOR PERITONEAL DIALYSIS
A4722	DIALYSATE SOLUTION, ANY CONCENTRATION OF DEXTROSE, FLUID VOLUME GREATER THAN 1999CC BUT LESS THAN OR EQUAL TO 2999CC, FOR PERITONEAL DIALYSIS
A4723	DIALYSATE SOLUTION, ANY CONCENTRATION OF DEXTROSE, FLUID VOLUME GREATER THAN 2999CC BUT LESS THAN OR EQUAL TO 3999CC, FOR PERITONEAL DIALYSIS

A4724	DIALYSATE SOLUTION, ANY CONCENTRATION OF DEXTROSE, FLUID VOLUME GREATER THAN 3999CC BUT LESS THAN OR EQUAL TO 4999CC, FOR PERITONEAL DIALYSIS
A4725	DIALYSATE SOLUTION, ANY CONCENTRATION OF DEXTROSE, FLUID VOLUME GREATER THAN 4999CC BUT LESS THAN OR EQUAL TO 5999CC, FOR PERITONEAL DIALYSIS
A4726	DIALYSATE SOLUTION, ANY CONCENTRATION OF DEXTROSE, FLUID VOLUME GREATER THAN 5999CC, FOR PERITONEAL DIALYSIS
A4728	DIALYSATE SOLUTION, NON-DEXTROSE CONTAINING, 500 ML
A4730	FISTULA CANNULATION SET FOR HEMODIALYSIS, EACH
A4736	TOPICAL ANESTHETIC, FOR DIALYSIS, PER GRAM
A4737	INJECTABLE ANESTHETIC, FOR DIALYSIS, PER 10 ML
A4740	SHUNT ACCESSORY, FOR HEMODIALYSIS, ANY TYPE, EACH
A4750	BLOOD TUBING, ARTERIAL OR VENOUS, FOR HEMODIALYSIS, EACH
A4755	BLOOD TUBING, ARTERIAL AND VENOUS COMBINED, FOR HEMODIALYSIS, EACH
A4760	DIALYSATE SOLUTION TEST KIT, FOR PERITONEAL DIALYSIS, ANY TYPE, EACH
A4765	DIALYSATE CONCENTRATE, POWDER, ADDITIVE FOR PERITONEAL DIALYSIS, PER PACKET
A4766	DIALYSATE CONCENTRATE, SOLUTION, ADDITIVE FOR PERITONEAL DIALYSIS, PER 10 ML
A4770	BLOOD COLLECTION TUBE, VACUUM, FOR DIALYSIS, PER 50
A4771	SERUM CLOTTING TIME TUBE, FOR DIALYSIS, PER 50
A4772	BLOOD GLUCOSE TEST STRIPS, FOR DIALYSIS, PER 50
A4773	OCCULT BLOOD TEST STRIPS, FOR DIALYSIS, PER 50
A4774	AMMONIA TEST STRIPS, FOR DIALYSIS, PER 50
A4802	PROTAMINE SULFATE, FOR HEMODIALYSIS, PER 50 MG
A4860	DISPOSABLE CATHETER TIPS FOR PERITONEAL DIALYSIS, PER 10
A4870	PLUMBING AND/OR ELECTRICAL WORK FOR HOME HEMODIALYSIS EQUIPMENT
A4890	CONTRACTS, REPAIR AND MAINTENANCE, FOR HEMODIALYSIS EQUIPMENT
A4911	DRAIN BAG/BOTTLE, FOR DIALYSIS, EACH
A4913	MISCELLANEOUS DIALYSIS SUPPLIES, NOT OTHERWISE SPECIFIED
A4918	VENOUS PRESSURE CLAMP, FOR HEMODIALYSIS, EACH

A4927	GLOVES, NON-STERILE, PER 100
A4928	SURGICAL MASK, PER 20
A4929	TOURNIQUET FOR DIALYSIS, EACH
A4930	GLOVES, STERILE, PER PAIR
A4931	ORAL THERMOMETER, REUSABLE, ANY TYPE, EACH
A6204	SURGICAL DRESSING
A6250	SKIN SEALANTS, PROTECTANTS, MOISTURIZERS, OINTMENTS, ANY TYPE, ANY SIZE
A6260	WOUND CLEANSERS, STERILE, ANY TYPE, ANY SIZE
E1500	CENTRIFUGE, FOR DIALYSIS
E1510	KIDNEY, DIALYSATE DELIVERY SYST. KIDNEY MACHINE, PUMP RECIRCULATING, AIR REMOVAL SYST, FLOWRATE METER, POWER OFF, HEATER AND TEMPERATURE CONTROL WITH ALARM, I.V. POLES, PRESSURE GAUGE, CONCENTRATE CONTAINER
E1520	HEPARIN INFUSION PUMP FOR HEMODIALYSIS
E1530	AIR BUBBLE DETECTOR FOR HEMODIALYSIS, EACH, REPLACEMENT
E1540	PRESSURE ALARM FOR HEMODIALYSIS, EACH, REPLACEMENT
E1550	BATH CONDUCTIVITY METER FOR HEMODIALYSIS, EACH
E1560	BLOOD LEAK DETECTOR FOR HEMODIALYSIS, EACH, REPLACEMENT
E1570	ADJUSTABLE CHAIR, FOR ESRD PATIENTS
E1575	TRANSDUCER PROTECTORS/FLUID BARRIERS, FOR HEMODIALYSIS, ANY SIZE, PER 10
E1580	UNIPUNCTURE CONTROL SYSTEM FOR HEMODIALYSIS
E1590	HEMODIALYSIS MACHINE
E1592	AUTOMATIC INTERMITTENT PERITONEAL DIALYSIS SYSTEM
E1594	CYCLER DIALYSIS MACHINE FOR PERITONEAL DIALYSIS
E1600	DELIVERY AND/OR INSTALLATION CHARGES FOR HEMODIALYSIS EQUIPMENT
E1610	REVERSE OSMOSIS WATER PURIFICATION SYSTEM, FOR HEMODIALYSIS
E1615	DEIONIZER WATER PURIFICATION SYSTEM, FOR HEMODIALYSIS
E1620	BLOOD PUMP FOR HEMODIALYSIS, REPLACEMENT
E1625	WATER SOFTENING SYSTEM, FOR HEMODIALYSIS
E1630	RECIPROCATING PERITONEAL DIALYSIS SYSTEM
E1632	WEARABLE ARTIFICIAL KIDNEY, EACH
E1634	PERITONEAL DIALYSIS CLAMPS, EACH
E1635	COMPACT (PORTABLE) TRAVEL HEMODIALYZER SYSTEM

E1636	SORBENT CARTRIDGES, FOR HEMODIALYSIS, PER 10
E1637	HEMOSTATS, EACH
E1639	SCALE, EACH
E1699	DIALYSIS EQUIPMENT, NOT OTHERWISE SPECIFIED

LABS SUBJECT TO ESRD CONSOLIDATED BILLING

CPT/ HCPCS	Short Description
80047	Basic Metabolic Panel (Calcium, ionized)
80048	Basic Metabolic Panel (Calcium, total)
80051	Electrolyte Panel
80053	Comprehensive Metabolic Panel
<i>80061¹</i>	<i>Lipid Panel</i>
80069	Renal Function Panel
80076	Hepatic Function Panel
82040	Assay of serum albumin
82108	Assay of aluminum
82306	Vitamin d, 25 hydroxy
82310	Assay of calcium
82330	Assay of calcium, Ionized
82374	Assay, blood carbon dioxide
82379	Assay of carnitine
82435	Assay of blood chloride
82565	Assay of creatinine
82570	Assay of urine creatinine
82575	Creatinine clearance test
82607	Vitamin B-12
82652	Vit d 1, 25-dihydroxy
82668	Assay of erythropoietin
82728	Assay of ferritin
82746	Blood folic acid serum
83540	Assay of iron
83550	Iron binding test
83735	Assay of magnesium
83970	Assay of parathormone
84075	Assay alkaline phosphatase
84100	Assay of phosphorus
84132	Assay of serum potassium

84134	Assay of prealbumin
84155	Assay of protein, serum
84157	Assay of protein by other source
84295	Assay of serum sodium
84466	Assay of transferrin
84520	Assay of urea nitrogen
84540	Assay of urine/urea-n
84545	Urea-N clearance test
85014	Hematocrit
85018	Hemoglobin
85025	Complete (cbc), automated (Hgb, Hct, RBC, WBC, and Platelet count) and automated differential WBC count.
85027	Complete (cbc), automated (Hgb, Hct, RBC, WBC, and Platelet count)
85041	Automated rbc count
85044	Manual reticulocyte count
85045	Automated reticulocyte count
85046	Reticyte/hgb concentrate
85048	Automated leukocyte count
86704	Hep b core antibody, total
86705	Hep b core antibody, igm
86706	Hep b surface antibody
87040	Blood culture for bacteria
87070	Culture, bacteria, other
87071	Culture bacteri aerobic othr
87073	Culture bacteria anaerobic
87075	Cultr bacteria, except blood
87076	Culture anaerobe ident, each
87077	Culture aerobic identify
87081	Culture screen only
87340	Hepatitis b surface ag, eia
G0306	CBC/diff wbc w/o platelet
G0307	CBC without platelet

DRUGS SUBJECT TO ESRD CONSOLIDATED BILLING

Category	HCPDS	Title
Access Management	C9121	INJ ARGATROBAN
	J1642	INJ HEPARIN SODIUM PER 10 U
	J1644	INJ HEPARIN SODIUM PER 1000U
	J1945	LEPIRIDUN
	J2993	RETEPLASE INJECTION
	J2997	ALTEPLASE RECOMBINANT
	J3364	UROKINASE 5000 IU INJECTION
	J3365	UROKINASE 250,000 IU INJ
Anemia Management	J0882	DARBEPOETIN
	<i>J0886²</i>	<i>EPO</i>
	J0887	INJ. EPOETIN BETA (FOR ESRD ON DIALYSIS), 1 MCG
	J1439	INJ FERRIC CARBOXYMALTOSE, 1MG
	J1750	IRON DEXTRAN
	<i>J1443³</i>	<i>INJ. FERRIC PYROPHOSPHATE CIT</i>
	J1756	IRON SUCROSE INJECTION
	J2916	NA FERRIC GLUCONATE COMPLEX
	J3420	VITAMIN B12 INJECTION
	Q0139	FERUMOXYTOL
	<i>Q9976²</i>	<i>INJ. FERRIC PYROPHOSPHATE CIT</i>
Q4081	EPO	
Bone and Mineral Metabolism	J0610	CALCIUM GLUCONATE INJECTION
	J0630	CALCITONIN SALMON INJECTION
	J0635	CALCITRIOL
	J0636	INJ CALCITRIOL PER 0.1 MCG
	J0895	DEFEROXAMINE MESYLATE INJ
	J1270	INJECTION, DOXERCALCIFEROL
	J1740	IBANDRONATE SODIUM
	J2430	PAMIDRONATE DISODIUM /30 MG
	J2501	PARICALCITOL
	J3487	ZOLEDRONIC ACID
	S0169	CALCITRIOL
	J1955	INJ LEVOCARNITINE PER 1 GM
Cellular Management	J0878	DAPTOMYCIN
	J3370	VANCOMYCIN HCL INJECTION
Anti-Infectives	A4802	INJ PROTAMINE SULFATE
	J0670	INJ MEPIVACAINE HYDROCHLORIDE
	J1200	INJ DIPHENHYDRAMINE HCL
	J1205	INJ CHLOROTHIAZIDE SODIUM
Composite Rate Drugs and Biologicals		

J1240	INJ DIMENHYDRINATE
J1940	INJ FUROSEMIDE
J2001	INJ LIDOCAINE HCL FOR INTRAVENOUS INFUSION, 10 MG
J2150	INJ MANNITOL
J2720	INJ PROTAMINE SULFATE
J2795	INJ ROPIVACAINE HYDROCHLORIDE
J3410	INJ HYDROXYZINE HCL
J3480	INJ. POTASSIUM CHLORIDE, PER 2 MEQ.
Q0163	DIPHENHYDRAMINE HYDROCHLORIDE

¹ Effective January 1, 2016, this item or service is no longer subject to the ESRD PPS consolidated billing requirements.

² Effective January 1, 2016, J0886 and Q9976 was terminated therefore it is no longer subject to the ESRD PPS consolidated billing requirements.

³ Effective January 1, 2016, this item or service is subject to the ESRD PPS consolidated billing requirements.